Evidence map›Paper›PMID 32818152›Full record

ArticleBMJ open ophthalmology2020

Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4.

Etsuko Terao, Shunsuke Nakakura, Yasuko Fujisawa, Yuki Nagata, Kanae Ueda, Yui Kobayashi, Satomi Oogi, Saki Dote, Miku Shiraishi, Hitoshi Tabuchi and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Prostanoid receptor agonists for glaucoma treatment.Japanese journal of ophthalmology · 2021
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Etsuko TeraoDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
Shunsuke NakakuraDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.ORCID 0000-0002-1094-1862
Yasuko FujisawaDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
Yuki NagataDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
Kanae UedaDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
Yui KobayashiDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
Satomi OogiDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
Saki DoteDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
Miku ShiraishiDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
Hitoshi TabuchiDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
Tsuyoshi YonedaDepartment of Sensory Science, Kawasaki University of Medical Welfare, Kurashiki, Japan.
Atsuki FukushimaDepartment of Ophthalmology, Kochi Medical School, Kochi University, Nankoku, Japan.
Ryo AsaokaDepartment of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-7182-1912
Yoshiaki KiuchiDepartment of Ophthalmology, Hiroshima University, Hiroshima, Japan.
Hiroshima University · JPKawasaki University of Medical Welfare · JPKōchi University · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe investigated the detailed time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002% (omidenepag), a selective prostaglandin E2 receptor 2 agonist. METHODS AND ANALYSIS: We recruited 34 healthy subjects and administered omidenepag in the right eye and ripasudil 0.4% in the left eye. We evaluated conjunctival hyperemia using slit-lamp photography at baseline and after 15, 30, 60, 120, 180 and 360 min. The conjunctival hyperemia score was graded by three independent observers using a scale from 0 (none) to 3 (severe). We also evaluated conjunctival hyperemia by the pixel coverage of conjunctival blood vessels (per cent coverage) determined using a conjunctival hyperemia-analysing software.

resultsIn omidenepag, the conjunctival hyperemia score and per cent coverage peaked at both 30 min (mean score±SD: 1.57±0.67 and 11.90%±3.66%, respectively) and then gradually decreased at 60 min (10.79%±3.32%) and 120 min (1.10±0.52) when they reached a level that was not significantly different from the baseline values. For ripasudil 0.4%, the peak time of the conjunctival hyperemia score and per cent coverage were both at 15 min (score: 2.42±0.54 and 15.26%±3.38%). The degree of conjunctival hyperemia was significantly higher for ripasudil 0.4% than that for omidenepag from 15 to 30 min in both the conjunctival hyperemia score and per cent coverage (p<0.007 by Bonferroni correction).

conclusionConjunctival hyperemia induced by omidenepag gradually peaks to moderate severity, though weaker compared with that induced by ripasudil 0.4%, and subsides relatively quickly.

Indexed as

conjunctivadrugsglaucomaocular surfacepharmacology

Identifiers

PMID32818152
PMCPMC7398095
OpenAlexW3046519200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.